EP2792360A1 — (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
Assigned to IP Gesellschaft fuer Management mbH · Expires 2014-10-22 · 12y expired
What this patent protects
The invention relates to an administration unit comprising a compound of formula and/or pharmaceutically acceptable salts thereof, and to a packaging comprising the administration unit according to the invention.
USPTO Abstract
The invention relates to an administration unit comprising a compound of formula and/or pharmaceutically acceptable salts thereof, and to a packaging comprising the administration unit according to the invention.
Drugs covered by this patent
- nilotinib-hydrochloride (Nilotinib Hydrochloride) · Jan Beumer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.